{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:23:04Z","timestamp":1785759784747,"version":"3.56.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,9,1]]},"DOI":"10.1001\/jama.2020.9840","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T15:08:07Z","timestamp":1598972887000},"page":"895","source":"Crossref","is-referenced-by-count":22,"title":["Incidence of Malformations After Early Pregnancy Exposure to Modafinil in Sweden and Norway"],"prefix":"10.1001","volume":"324","author":[{"given":"Carolyn E.","family":"Cesta","sequence":"first","affiliation":[{"name":"Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Engeland","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases and Aging, Norwegian Institute of Public Health, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Kieler","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Reutfors","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Furu","sequence":"additional","affiliation":[{"name":"Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"jld200058r4","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jama.2019.20008","article-title":"First-trimester pregnancy exposure to modafinil and risk of congenital malformations.","volume":"323","author":"Damkier","year":"2020","journal-title":"JAMA"},{"key":"jld200058r5","doi-asserted-by":"publisher","first-page":"h1798","DOI":"10.1136\/bmj.h1798","article-title":"Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design.","volume":"350","author":"Furu","year":"2015","journal-title":"BMJ"},{"issue":"2","key":"jld200058r6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamapsychiatry.2017.3644","article-title":"Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the International Pregnancy Safety Study Consortium.","volume":"75","author":"Huybrechts","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"jld200058r1","unstructured":"Teva Pharmaceuticals Ireland. Modafinil: potential risk of congenital malformations when administered during pregnancy. Accessed February 26, 2020. http:\/\/www.hpra.ie\/docs\/default-source\/default-document-library\/important-safety-information-modafinil99170c2697826eee9b55ff00008c97d0.pdf"},{"key":"jld200058r2","unstructured":"European Medicines Agency; Pharmacovigilance Risk Assessment Committee. New product information wording\u2014extracts from PRAC recommendations on signals: 2. modafinil\u2014evaluation of data on foetal outcomes including congenital anomalies from a single observational study in the US (EPITT No. 19367). Accessed February 26, 2020. https:\/\/www.ema.europa.eu\/en\/documents\/other\/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_en.pdf"},{"key":"jld200058r3","unstructured":"Government of Canada. Recalls and safety alerts: ALERTEC (modafinil) and the risk of congenital anomalies. Accessed February 26, 2020. https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2019\/70201a-eng.php"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2769999\/jama_cesta_2020_ld_200058_1609349128.00227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T23:54:58Z","timestamp":1610063698000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2769999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":6,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.9840","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}